Agenus (AGEN) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
- Oil prices gain on attacks in Saudi Arabia, Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Agenus (AGEN) Announces Positive Efficacy Data from Glaxo (GSK) Second Shingles Vaccine Phase 3
October 27, 2015 6:56 AM EDTAgenus (NASDAQ: AGEN) announced that GlaxoSmithKlines plc (NYSE: GSK) second pivotal Phase III efficacy study of its shingles vaccine candidate containing Agenus QS-21 Stimulon® adjuvant demonstrated 90% overall efficacy against shingles compared to placebo. In this trial known as ZOE-70 (Zoster efficacy in adults aged 70 years and... More



